Molecular structure of Vincristine Sulfate, CAS Number: 2068-78-2
Vincristine Sulfate (CAS 2068-78-2)
See product citations (15)
Alternate Names:
VCR . sulfate;Leukocristine . sulfate
Application:
Vincristine Sulfate is a cell cycle arresting, apoptotic inducing alkaloid
CAS Number:
2068-78-2
Purity:
≥98%
Molecular Weight:
923.04
Molecular Formula:
C46H56N4O10•H2SO4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Vincristine Sulfate, a dimeric Vinca alkaloid, may act to bind to Tubulin via a protein self association reaction. This compound acts as a Tubuiln inhibitor by binding to sites at the ends of microtubules, which regulate the inhibition of Tubulin dimer addition to microtubule ends. Experiments have reported Vincristine Sulfate to demonstrate a capacity to suppress growth of proliferating cells through marked apoptosis and cell cycle arrest at G2/M. The cell death caused by this agent seems to result in a sustained accumulation of endogenous ceramide levels. Ceramide, has been proposed as a lipid second messenger with specific antiproliferative mediating responses. Vincristine Sulfate is an inhibitor of MAO. Vincristine Sulfate is also a substrate of PGP and CYP3A4.
Vincristine Sulfate (CAS 2068-78-2) References
- The morphological effects of vincristine sulfate on canine bone marrow cells. | Alleman, AR. and Harvey, JW. 1993. Vet Clin Pathol. 22: 36-41. PMID: 12669276
- Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. | Li, Y., et al. 1992. Biochem Biophys Res Commun. 187: 722-9. PMID: 1530630
- Vincristine sulfate as a possible cause of optic neuropathy. | Weisfeld-Adams, JD., et al. 2007. Pediatr Blood Cancer. 48: 238-40. PMID: 16206187
- Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. | Himes, RH. 1991. Pharmacol Ther. 51: 257-67. PMID: 1784631
- PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. | Song, X., et al. 2008. Int J Pharm. 350: 320-9. PMID: 17913411
- Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. | Ling, G., et al. 2010. J Control Release. 148: 241-8. PMID: 20727928
- Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. | Chen, J., et al. 2012. Eur J Pharm Sci. 47: 430-43. PMID: 22796217
- Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. | Silverman, JA. and Deitcher, SR. 2013. Cancer Chemother Pharmacol. 71: 555-64. PMID: 23212117
- Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance. | Wang, Y., et al. 2014. Mol Pharm. 11: 885-94. PMID: 24483832
- Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). | Hantrakul, S., et al. 2014. J Vet Med Sci. 76: 1549-53. PMID: 25649934
- Conventional-Vincristine Sulfate vs. Modified Protocol of Vincristine Sulfate and L-Asparaginase in Canine Transmissible Venereal Tumor. | Setthawongsin, C., et al. 2019. Front Vet Sci. 6: 300. PMID: 31620453
- Pharmacokinetics of vincristine sulfate in adult cancer patients. | Sethi, VS., et al. 1981. Cancer Res. 41: 3551-5. PMID: 7260915
- Pharmacokinetics of vincristine sulfate in children. | Sethi, VS. and Kimball, JC. 1981. Cancer Chemother Pharmacol. 6: 111-5. PMID: 7307229
- Bcl-2 interrupts the ceramide-mediated pathway of cell death. | Zhang, J., et al. 1996. Proc Natl Acad Sci U S A. 93: 5325-8. PMID: 8643573
- Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. | Embree, L., et al. 1998. Cancer Chemother Pharmacol. 41: 347-52. PMID: 9523729
Inhibitor of:
MAO, and Tubulin.Substrate of:
CYP3A4, Enzyme, and PGP.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Vincristine Sulfate, 5 mg | sc-201434 | 5 mg | $120.00 | |||
Vincristine Sulfate, 25 mg | sc-201434A | 25 mg | $335.00 |